DeCure's autonomous Neuro AI scientist is researching a drug-repurposing hypothesis for juvenile absence epilepsy — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleJuvenile absence epilepsy maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for juvenile absence epilepsy is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
A 2003 review states that in juvenile absence epilepsy, seizure control is often achieved but lifelong treatment is usually required, whereas in childhood absence epilepsy roughly two thirds of children enter long-term remission. Psychosocial outcome is often poor even in the more benign forms, and remission of epilepsy does not prevent psychosocial morbidity.
A 2018 retrospective analysis of 135 outpatients with absence epilepsy (53 with juvenile onset, 82 with childhood onset) followed for a median of 45.4 years found that 53% of all patients achieved five-year terminal seizure remission, and only 16% did so without antiepileptic medication. Median age at last seizure was lower in childhood onset (37.7 years) than in juvenile onset (44.4 years, p ≤ 0.01), but rates and duration of terminal remission were similar between the two groups. The pyknoleptic versus non-pyknoleptic course of absence seizures made no difference to long-term seizure outcome. The only factor associated with terminal five-year remission in multivariate analysis was higher age at investigation. Psychosocial outcomes did not differ significantly between subgroups. The authors conclude that if absence epilepsy persists beyond adolescence, long-term seizure and psychosocial outcome do not differ between childhood and juvenile onset or between pyknoleptic and non-pyknoleptic courses.
A 1997 letter to the editor criticises a study on childhood absence epilepsy for possibly including patients with encephalopathy causing absence seizures, and notes that some authors believe one third of cases may be misclassified. A 2010 genetic study of five consanguineous Tunisian families with childhood absence epilepsy excluded four candidate genes (CACNG2, CACNA1A, CACNB4, CACNA2D2) that cause autosomal recessive absence seizures in mice, leaving the causative gene or genes unknown.
What is still missing is a clear genetic or biomarker basis to stratify juvenile absence epilepsy from other absence syndromes, prospective data on which patients will require lifelong treatment versus those who will remit, and trials designed to improve the poor psychosocial outcomes that persist even when seizures are controlled.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · 2003 · 56 citations · open access
Natural History of Absence Epilepsy in Children
AbstractAbsence seizures may be seen in a variety of epileptic syndromes in childhood. Identification of the specific syndrome is important to determine medical prognosis. With childhood absence epilepsy, approximately two thirds of children can be expected to enter long-term remission, while in juvenile absence epilepsy, seizure control is often achieved, however, lifelong treatment is usually required. Other absence syndromes have a poorer prognosis, with lower rates of seizure control and remission. Psychosocial outcome is often poor, even in patients with more benign forms of absence epilepsy. Remission of epilepsy does not preclude psychosocial morbidity.
Absence epilepsy beyond adolescence: an outcome analysis after 45 years of follow-up
AbstractOBJECTIVES: Depending on patient age at onset, absence epilepsy is subdivided into childhood and juvenile forms. Absence seizures can occur several times per day (pyknoleptic course) or less frequently than daily (non-pyknoleptic course). Seizures typically terminate before adulthood, but a quarter of patients need ongoing treatment beyond adolescence. Little is known about their long-term seizure and psychosocial outcome. METHODS: Files of 135 outpatients with absence epilepsy (76 females; 123 had additional generalised tonic-clonic seizures) were retrospectively analysed after a median follow-up of 45.4 years (IQR: 31.9-56.2). Eighty-two subjects completed an additional interview. Patients were dichotomised according to age at epilepsy onset (childhood: n=82; juvenile: n=53) and course of absence seizures (pyknoleptic: n=80; non-pyknoleptic: n=55). RESULTS: Among all patients, 53% achieved 5-year terminal seizure remission, 16% without antiepileptic medication. Median age at last seizure was lower in patients with childhood onset of absence epilepsy (37.7 years) versus juvenile onset (44.4 years; P≤0.01). However, rates and duration of terminal seizure remission were similar. Pyknoleptic versus non-pyknoleptic course of absence seizures made no difference for long-term seizure outcome. Multivariate analysis identified only higher age at investigation to be associated with terminal 5-year seizure remission. Regarding aspects of psychosocial outcome, there were no significant differences between the respective subgroups. CONCLUSIONS: These data indicate that if absence epilepsy persists beyond adolescence, long-term seizure and psychosocial outcome do not differ between childhood and juvenile onset or between pyknoleptic and non-pyknoleptic course of absence epilepsy. However, higher patient age increases the chance of terminal seizure remission.
Familial form of typical childhood absence epilepsy in a consanguineous context
AbstractCausative genes for childhood absence epilepsy (CAE) are unknown partly because families are small or phenotypically heterogeneous. In five consanguineous Tunisian families with at least two sibs with CAE, 14 patients fulfilled the diagnostic criteria for CAE (Epilepsia 1989; 30:389-399). Linkage analyses or direct sequencing excluded CACNG2, CACNA1A, CACNB4, and CACNA2D2, orthologs of genes responsible for autosomal recessive (AR) absence seizures in mice. These families will help identify (a) gene(s) responsible for CAE.
International Journal of Risk & Safety in Medicine · 2012 · 5 citations
Pharmacoepidemiology of antiepileptic drugs in children: Comparative analysis of efficacy and safety
AbstractPharmacoepidemiology analysis of efficacy and safety of antiepileptics was carried out in children (3 months–18 years old) registered with municipal children's epilepsy services: 548 children in 2005, 718 – In 2007 and 32 – In 2011. We used remission lasting for 1 year or longer, and 3 years or longer as primary effectiveness outcomes, and total number of people with adverse effects as a safety outcome. We found no advantages of newer antiepileptics over the older ones in terms of either efficacy or safety. Long-term follow up (more than 3 years) showed higher treatment response rate in patients with childhood versus juvenile absence epilepsy.
Long-term prognosis of typical childhood absence epilepsy
AbstractTo the Editor: We read with interest the article on long-term prognosis of typical childhood absence epilepsy (CAE) by Wirrell et al.,1 who concluded that 65% of children with CAE will have remission and that nearly half of those without remission will develop juvenile myoclonic epilepsy (JME). It seems the authors categorized patients as CAE too freely: the patients with cognitive dysfunction and slow background activity on EEG may have a fixed encephalopathy causing absence seizures (AS). In fact, some authors believe that one third …
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
